Not yet recruiting
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
NCT06726330· Centre Oscar Lambret· Source
Not yet recruiting
Comparison of Telerehabilitation and Usual Rehabilitation After Knee or Hip Surgery
NCT07902505· Centre Hospitalier de Valenciennes· Source
Not yet recruiting
ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.
NCT07737964· Phase 3· University Hospital, Montpellier· Source
Not yet recruiting
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.
2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Not yet recruiting
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
NCT07359456· Phase 2· UNICANCER· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· Phase 3· Novartis Pharmaceuticals· Source
Not yet recruiting
Bosentan in the Treatment of Giant Cell Arteritis
NCT06957002· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
NCT07451847· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
NCT06940661· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
NCT06350630· Phase 2· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment
NCT06995443· Centre Hospitalier de Valenciennes· Source
Recruiting
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
NCT06764693· AbbVie· Source
Active, not recruiting
Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting
NCT06639620· AbbVie· Source
Not yet recruiting
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
NCT06045858· Phase 3· University Hospital, Caen· Source
Active, not recruiting
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source
Active, not recruiting
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Recruiting
UVB: treatment of UVeitis in Behçet’s diseases with biologic
2024-513371-41-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
TocilizuMab discontinuAtion in GIant Cell Arteritis
2023-505515-21-00· Phase 3· Centre Hospitalier Universitaire De Dijon· Source
Recruiting
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
NCT05946564· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171· Phase 2· Alentis Therapeutics AG· Source
Recruiting
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
NCT05387954· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
NCT05732727· Phase 3· University Hospital, Tours· Source
Active, not recruiting
An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
NCT05669794· AbbVie· Source
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· Phase 3· UNICANCER· Source
Recruiting
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916· Acute Leukemia French Association· Source
Recruiting
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
NCT04702256· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT04621188· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
Atrasentan in Patients With IgA Nephropathy
NCT04573478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients
NCT03970577· Phase 2· Assistance Publique Hopitaux De Paris· Source
Recruiting
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)
NCT04167007· Phase 2/3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
NCT04083339· Phase 3· Applied Therapeutics, Inc.· Source
Recruiting
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
NCT03290456· Phase 3· Hospices Civils de Lyon· Source
Active, not recruiting
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
NCT03323476· Phase 3· Centre Hospitalier Departemental Vendee· Source
Recruiting
GRAALL2014
NCT02617004· Phase 2· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00005584· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source